HAP Trading’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-65,000
Closed -$2K 675
2024
Q2
$2K Hold
65,000
﹤0.01% 622
2024
Q1
$19.5K Sell
65,000
-200
-0.3% -$1.02K ﹤0.01% 528
2023
Q4
$95.9K Buy
+65,200
New +$302K 0.02% 375
2022
Q3
Sell
-14,000
Closed -$22K 1698
2022
Q2
$22K Buy
+14,000
New +$119K ﹤0.01% 1303
2022
Q1
Sell
-125,400
Closed -$7K 2160
2021
Q4
$7K Buy
125,400
+6,900
+6% +$105K ﹤0.01% 2134
2021
Q3
$159K Buy
118,500
+106,100
+856% +$1.88M 0.01% 1112
2021
Q2
$4K Buy
+12,400
New +$342K ﹤0.01% 2174

Other funds holding ABCL

HAP Trading's ABCL Position: Q3 2021 in Review

HAP Trading sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 11,474 shares — an estimated $203K sold.

HAP Trading first reported a position in ABCL in Q2 2021 and held it in 1 quarter. The position peaked at $252K in Q2 2021. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.

  • HAP Trading reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
  • HAP Trading sold 11,474 AbCellera Biologics shares in Q3 2021, an estimated $203K.
  • HAP Trading first reported a position in AbCellera Biologics in Q2 2021 and held it in 1 quarter.
  • HAP Trading's AbCellera Biologics position peaked at $252K in Q2 2021.
  • 116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.

Based on HAP Trading's 13F filing for Q3 2021, filed 10 Nov 2021.